Comparative Analysis of Five Brands of Lisinopril Tablets in Yemeni Market by G.Q., Othman
YEMENI JOURNAL FOR MEDICAL SCIENCES (2014) (8) 
25
YEMENI JOURNAL FOR MEDICAL SCIENCES 
http://ust.edu/ojs/index.php?journal=yjmp 
ORIGINAL ARTICLE 
Comparative Analysis of Five Brands of Lisinopril 
Tablets in Yemeni Market 
Gamil Q. Othman1,*
1
 Department of Pharmaceutical science, Faculty of pharmacy, University of Science and 
Technology, Sana’a, Yemen 
* 
Correspondence author: 
E-mail: gamilqasem@yahoo.com 
_____________________________________________________________________________________________________________________ 
Abstract: 
Background: In poor countries such as Yemen, the cost of drugs is a factor affecting the patient’s decision to buy it 
and generic medicines are introduced as cheaper alternatives to the high cost brands. Thus, this study aimed to 
identify the physicochemical similarity of five products of tablets comprising much Lisinopril (antihypertensive) 
taken from various pharmacies where retail medications are rendered to the Yemeni market. 
Methods: In this study, the researcher has conducted an assessment to the quality and physicochemical uniformity of 
five various products of Lisinopril tablets.  The uniformity of weight, friability, crushing strength, disintegration and 
dissolution tests and chemical test of the tablets were evaluated as major factors.  
Results: Results showed that all five products of the Lisinopril 5 mg tablets were compatible to the standards of 
British Pharmacopoeia (BP) in terms of uniformity of weight (91.04 – 137.4%), the crushing strength/hardness test 
(3.93 – 7.92%) and the friability test (0.18 – 0.29%).  All the products have showed good results about the 
disintegration time (15 sec – 7 min and 5 sec) and dissolution test (96.67 – 103.7%). The active content of products 
ranged from 102.8 – 108%. 
Conclusion: The five brands of Lisinopril 5mg tablets, which were analyzed, have matched the BP quality standards 
and were physically and chemically consistent.  Thus, cheap generic medicine can be used as alternative for 
innovator products. 
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1. Introduction
The increasing numbers of generic drug 
products are available in the market, making it 
possible to people involved in providing healthcare 
services to select a particular generic drug from 
several equivalent products (1). Internationally, 
statistics found that generic drugs are dramatically 
used, giving rise to a high cost of drug budgets. 
Since the use of generic drugs is a lower cost than 
the new products or brands, great savings in health 
care payment can be made. However, plenty of 
medical doctors have a doubt of quality of generic 
drugs (2, 3) and their reliability and to replace a 
particular drug (4). Empirical studies found that 
generic medications have lower therapeutic 
efficiency and value than branded products (5, 6) 
even though, they are bio-equivalents of their 
innovative peers and are produced under good 
manufacturing practices (7). 
 Statistics reported by countries in Central and 
Eastern Europe and some countries from the 
former Soviet Union showed that manufacturers of 
imported branded products promote that generic 
drugs are lower quality compared to the branded 
ones (8). To obtain approval from FDA for a 
generic drug, it must match the newly-produced 
drug in active ingredients, strength, dosage form, 
route of administration, the same usage 
indications, bioequivalent meet, batch 
requirements for identity, purity, quality and be 
manufactured in accordance with the strict 
standards of FDA’s good manufacturing practice 
regulations required for innovative products (9).In 
Yemen as a poor country, the cost is the key factor 
in defining the patient access to health care. Many 
people postpone the use of medications required 
because of the high cost of branded products. 
Under these circumstances, locally manufactured 
medicines are offered as alternative due to their 
low cost.  The objective of this study is to assess 
the quality of these five brands of Lisinopril tablets 
that are commercially available in the Yemeni 
market. 
2. Materials and Methods
Samples 
Five commercial products (brands) of 
Lisinopril, labelled to contain 5 mg per tablets, 
from different manufacturers were purchased and 
coded as A, B, C, D and E and then separated 
(Table 1). Various analytical methods and tests 
which are important for the development and 
manufacture of pharmaceutical formulations (10) 
were performed for all the tablet brands of five 
formulations in the study.  
Table 1. Country of origin, manufacture and expiry dates of five 
brands of list tablets 
Country Brand Code Strength (mg) Exp.  Date 
Sweden Zestril® A 5mg 12 \ 2014 
Yemen Lotensin® B 5mg 1\ 2014 
Yemen Lisistril® C 5mg 1 \ 2013 
Jordon zenoril® D 5mg 7 \ 2014 
India cipril® E 5mg 12 \ 2013 
Weight Variation Test 
All the products were subjected to a number of 
weight variation tests. Thus, any variation in the 
weight of each single tablet is evidence that there 
is a similar variation in the content of the drugs. It 
is possible to achieve better tablet hardness and 
friability through a strict control for the tablet 
weights (11). The appropriate ratio for the 
deviation of the tablet weigh whose  average  
weight  of  250  mg  or  above should  not  exceed  
5% (12). A weight test was performed individually 
for ten tablets which were selected from each of 
the product by using electronic balance (Kern, 
Germany, Model: D-72336). Their average 
weights were calculated. For all tablet products, 
the researcher used a mathematical equation for 
weight variation as follows (13): 
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Highest weight variation = (Highest weight − 
Average weight/Average weight) × 100 
Lowest weight variation = (Lowest weight − 
Average weight/Average weight) × 100 
Hardness test 
Hardness  refers to  the  strength  of  a  tablet  
to resist machine-driven  shocks  during  handling 
process of manufacturing, packaging and  shipping 
(14).  The adequate value of hardness or crushing 
strength of tablet is 4kg or above (15).  During the 
study, the researcher adopted a Tablet Breaking 
Force Tester to determine the hardness of all 
tablets, Germany (PHARMA TEST: PTB). For all 
categories, five tablets of each product were 
selected and their hardness was also indentified. 
Friability test 
Friability test is designed to assess the ability 
of a tablet resistance to abrasion in packing, 
handling and transporting.  In this study, the 
researcher adopted PHARMA TEST: PTB. 
Friabilator (Germany) to determine friability. The 
percentage (%) was the ratio of friability. Ten 
tablets for each brand were initially weighed and 
transferred into friabilator which was operated at 
25 rpm for 4 minutes (up to 100 revolutions).  The 
tablets were weighted weighting again. The 
following formula shows the ratio of their friability 
after being weighted (13): 
% Friability = (Weight before test − Weight after 
test/Weight before test) × 100 
In most cases, the substantial level of weight loss 
of conventional compressed tablet is not more than 
0.5 to 1% (14). 
Disintegration time test 
Disintegration refers to the tablet fraction 
process into smaller pieces. It is deemed to be the 
primary move to dissolution. The maximum 
disintegration  time  for USP  uncoated  tablet  
must  be  as  short  as  5  minutes but most of the 
tablets have a maximum disintegration  time  of  
30  minutes  (14).  The method used as defined in 
the USP/NF was (PHARMA TEST: PTZ S) 
(1980). For individual tablet of all the products, 
the average of disintegration instrument used 
amounted at 100 ml of 0.1N HCl whereas the 
temperature was maintained at 37±1°C all over the 
testing process.  The researcher, thus, selected six 
tablets of each product and placed them in each of 
the cylindrical tubes of the basket. In addition, the 
disc was also used. During the time test process, 
the researcher of this study recorded the time 
consumed to break each tablet into small pieces 
and pass out through the net. Calculation of the 
total disintegration time was performed for each 
tablet of the products (16). 
The dissolution rate test 
In most cases, test of dissolution is performed 
to define drug release pattern during a short period 
of time (17). In this experiment, the researcher 
used Dissolution Tester – Germany (PHARMA 
TEST: D-63512) to test dissolution rate of each 
tablet of all the products. In order to define the 
dissolution rate for each of the tablet products, an 
amount of 900 ml of phosphate buffer, pH 2 was 
used as a dissolution medium. The speed of the 
experiment was 50 rpm at temperature of 37±1ºC 
for individual test.  Besides, amount of 5 ml as 
samples was  taken  at  a  regular  time  period  of  
10  minutes  as pre-estimated. The same  formula  
continued  up  to  30  minutes  by  replacing  equal 
amount  of  fresh  dissolution  medium  (phosphate 
buffer,  pH 2).  As a result, the accepted samples 
were subjected to suitable dilution and analysis by 
using HPLC at 215 nm for Lisinopril.  Absorption 
was measured and the rate of drug release was 
calculated (17, 13). All measurements were 
performed in triplicate.  
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Content of uniformity test 
Content of uniformity of the active ingredient 
in tablets was carried out by HPLC (Shimadzu 
CLharASS-VP V6.12 SP3, Kyoto, Japan). The 
mobile phase consisted of (Mono basic phosphate 
buffer: Acetonitrile) (80:20) pH=2.0. The 
experiment showed that 2.0 ml/min was the 
aggregate rate, and 20 μl for the injection volume 
and 215 nm for the detection wavelengths 
(Lisinopril). ODS hypersil C18 Column 
(25cmx4.6mm packed with 10 µm silica) was used 
throughout the experiments. Tests for chemical 
compliance and content of dynamic ingredient 
uniformity were performed in accordance with the 
standard method specified in BP 2002.  
Data Analysis 
In this study, the researcher used the mean ± 
standard deviation to analyze data for weight 
uniformity test, friability, crushing strength and the 
disintegration and dissolution times of the tablets.  
3. Results
All  the  samples  used  for  the  study  were 
within  their  shelf  life at the  time of 
investigation. The results of the physicochemical 
properties of the various brands of Lisinopril are 
presented in Table 2 and 3. 
The uniformity of weight determination for all 
brands of Lisinopril tablets ranges from 91.04% to 
137.4. The tablet crushing strength of A, B, C, D 
and E brands of Lisinopril ranged from 3.93 to 
7.92. All Lisinopril brands showed friability values 
ranging from 0.18% to 0.29% (Table 2).  
The overall disintegration time for Lisinopril 
tablet brands was between 15 seconds to 7 minutes 
and 50 seconds. It was observed that all the 
samples had the dissolution time ranging from 
96.67% to 103.7%. The active content of products 
was between 102.8% – 110.8 % (Table 3). 
Table 2. Results of unofficial quality control tests conducted on the 
Lisinopril tablets 
Code 
Weight 
uniformity test, 
mg  Mean (± SD) 
Crushing 
Strength Kgf 
Mean (± SD) 
Friability 
Mean (± SD) 
A 106.3 (0.9) 4.61(0.195) 0.188 (0.111) 
B 99.12 (1.8) 7.92 (0.608) 0.202(0.022) 
C 101.2 (2.5) 3.93 (0.452) 0.494(0. 0111) 
D 91.04 (2.2) 5.61(1.558) 0.231(0.192) 
E 137.4 (2.7) 4.12(0.564) 0.291(0.142) 
LIMITS >4 kg/cm2 <1% 
Table 3. Results of official quality control tests conducted on the 
Lisinopril Tablets 
Code
Disintegration 
Time (min) 
Mean (± SD) 
Dissolution after 
30 min 
 Mean (± SD) 
Active Content 
Uniformity test 
Mean (± SD) 
A 0.67 (0.102) 101.03 (1.04) 110.8 (1.414) 
B 0.25 (0.012) 103.7 (0.496) 110.4 (2.969) 
C 5.36 (0.313) 96.67 (4.21) 106.65 (6.611) 
D 7.50 (0.504) 103.43 (1.193) 106.87(2.142) 
E 4.44 (0.455) 99.68 (3.751) 102.8 (1.555) 
LIMITS < 15 >70% 95-105% 
4. Discussion
In this study, five branded products of 
Lisinopril tablets were selected from different 
pharmacies in Sana’a, Yemen. To assess and 
measure their quality control, five branded 
products were subjected to a number of tests. The 
result of the uniformity of weight for all the 
products showed compliance with the official 
specifications, since no brand deviated by up to 
5% from their means. A variation beyond the 
pharmacopoeia limits indicates unacceptable 
brands (18). All the products gave less than 
0.5%w/w loss in weight with the friability test 
determination, which is less than the official 
specification of 1%w/w, showing that all the 
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brands could resist abrasion without loss of tablet 
integrity (18). Suitable tablet hardness and 
reasonable friability are required for the 
satisfaction of consumers (19). The mean crushing 
strength which measures the level of hardness of 
the tablets is within the limits. In spite of the 
crushing strength is not an official method of tablet 
quality evaluation, it is still valuable in evaluating 
the integrity of tablet dosage forms (18).  
According to the specification of BP criteria, it has 
been shown that all the products have passed the 
disintegration test (18). The BP shows that not less 
than 70%w/w labeled content should dissolve at 45 
minutes. The study results has shown that the five 
brands reached more than 96% at 30 minutes 
which mean that the five brands may show good 
bioavailability profile in vivo. Dissolution rate has 
been reported to have a direct bearing on the 
bioavailability profile of tablet dosage forms as it 
can be used to predict the drug release pattern in 
vivo (20). 
According to the United State Pharmacopeia 
(USP), a Lisinopril tablet should contains not less 
than 90% and not more than 110% of Lisinopril. 
The results of the active content of products of the 
five brands in this study were within the limits 
which are in parallel with other studies  which  
demonstrated  brand-brand  equivalence  with  the  
innovator  product  (21, 22).  On the other hand,  
An empirical  study  on  85  generic  brands  from  
21  countries  found  that  91%  of  the  evaluated 
generic Piroxicam products failed to meet the 
routine in vitro USP quality assurance criteria for 
potency and/or  dissolution (23).  For such 
variation in dissolution, it may give rise to altered 
bioavailability and efficacy, and hence therapeutic 
failure. Furthermore, this study is incompatible 
with most recent studies that were conducted in 
Nigeria to compare between different products of 
Lisinopril tablets using HPLC and UV 
Spectrophotometer (24). 
5. Conclusion
This study concluded that Lisnopril from all 
brands demonstrated compliance with the official 
specifications in terms of uniformity of weight, 
hardness, disintegration, friability and chemical 
content. Thus, cheap generic medicine can be used 
as alternative for innovator products.  
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